BRCA2 and cancer: To identify effective drug combinations for BRCA-mutated cancer cells with de novo PARPi resistance, we tested the cellular effect of a panel of compounds either alone or in combination with PARPi in BRCA1-mutated HCC1937 and BRCA2-mutated HCT-15 cells.